Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Challenges Risperdal Penalty As First Amendment Violation

This article was originally published in The Pink Sheet Daily

Executive Summary

In case that could impact use of state unfair trade practices statutes, Janssen seeks Supreme Court review of South Carolina’s $124 million judgment for Risperdal labeling and Dear Doctor letter.

Advertisement

Related Content

PhRMA Fears 'Potentially Limitless' State Suits After Risperdal Case
J&J Risperdal Off-Label Settlement Includes Exec Pay Recoupment Provision
Risperdal Marketing Settlement Prevents Reprint Distribution Without sNDA
Risperdal Jury “Blown Away” By Testimony On Study Manipulation; J&J Settles Texas Suit
States Reap Rewards From Solo Suits Against Pharma; Atypical Antipsychotics May Offer Test Cases

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS078074

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel